Zobrazeno 1 - 10
of 342
pro vyhledávání: '"Shu‐Hsia Chen"'
Autor:
Yuanshuo Alice Wang, Ryan Neff, Won‐min Song, Xianxiao Zhou, Sezen Vatansever, Martin J. Walsh, Shu‐Hsia Chen, Bin Zhang
Publikováno v:
FEBS Open Bio, Vol 13, Iss 4, Pp 617-637 (2023)
Despite advancements in treatment, high‐grade serous ovarian cancer (HGSOC) is still characterized by poor patient outcomes. To understand the molecular heterogeneity of this disease, which underlies the challenge in selecting optimal treatments fo
Externí odkaz:
https://doaj.org/article/dea1b81e200d417e81dfe4bbc92c84c2
Autor:
Jianming Shao, Yitian Xu, Randall J. Olsen, Saro Kasparian, Kai Sun, Sunil Mathur, Jun Zhang, Chuan He, Shu-Hsia Chen, Eric H. Bernicker, Zejuan Li
Publikováno v:
Cells, Vol 13, Iss 8, p 715 (2024)
Immune checkpoint inhibitors (ICIs) drastically improve therapeutic outcomes for lung cancer, but accurately predicting individual patient responses to ICIs remains a challenge. We performed the genome-wide profiling of 5-hydroxymethylcytosine (5hmC)
Externí odkaz:
https://doaj.org/article/420b9c0e33134000b039a23175fb6661
Autor:
Hsuan‐Chen Liu, Simone Capuani, Andrew A. Badachhape, Nicola Di Trani, Daniel Davila Gonzalez, Robin S. Vander Pol, Dixita I. Viswanath, Shani Saunders, Nathanael Hernandez, Ketan B. Ghaghada, Shu‐Hsia Chen, Elizabeth Nance, Ananth V. Annapragada, Corrine Ying Xuan Chua, Alessandro Grattoni
Publikováno v:
Bioengineering & Translational Medicine, Vol 8, Iss 6, Pp n/a-n/a (2023)
Abstract Immune checkpoint inhibitors (ICI), pembrolizumab and atezolizumab, were recently approved for treatment‐refractory triple‐negative breast cancer (TNBC), where those with Programmed death‐ligand 1 (PD‐L1) positive early‐stage disea
Externí odkaz:
https://doaj.org/article/ae519761a40e482eaf80de02bca8ae93
Autor:
Qi Zhang, Jing Pan, Donghai Xiong, Junjun Zheng, Kristi N. McPherson, Sangbeom Lee, Mofei Huang, Yitian Xu, Shu-hsia Chen, Yian Wang, Lea Hildebrandt Ruiz, Ming You
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The development of chemopreventive strategies with the ability to prevent the progression of lung lesions to malignant cancers would reduce the mortality and morbidity resulting from this deadly disease. Delivery of microRNA (miRNA) by inhalation is
Externí odkaz:
https://doaj.org/article/1a18b2444578488ba5250547433fa266
Autor:
Hsuan‐Chen Liu, Daniel Davila Gonzalez, Dixita Ishani Viswanath, Robin Shae Vander Pol, Shani Zakiya Saunders, Nicola Di Trani, Yitian Xu, Junjun Zheng, Shu‐Hsia Chen, Corrine Ying Xuan Chua, Alessandro Grattoni
Publikováno v:
Advanced Science, Vol 10, Iss 9, Pp n/a-n/a (2023)
Abstract Agonist CD40 monoclonal antibodies (mAb) is a promising immunotherapeutic agent for cold‐to‐hot tumor immune microenvironment (TIME) conversion. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal cancer known as an immun
Externí odkaz:
https://doaj.org/article/486689090bc74e378bbc76afe2ddb100
Autor:
Joseph D. Butner, Prashant Dogra, Caroline Chung, Javier Ruiz-Ramírez, Sara Nizzero, Marija Plodinec, Xiaoxian Li, Ping-Ying Pan, Shu-hsia Chen, Vittorio Cristini, Bulent Ozpolat, George A. Calin, Zhihui Wang
Publikováno v:
Cell Death and Disease, Vol 13, Iss 5, Pp 1-10 (2022)
Abstract We present a multiscale agent-based model of ductal carcinoma in situ (DCIS) to study how key phenotypic and signaling pathways are involved in the early stages of disease progression. The model includes a phenotypic hierarchy, and key endoc
Externí odkaz:
https://doaj.org/article/ad476b3915b646a3b929e3fa31030c42
Autor:
Vipul K. Singh, Arshad Khan, Yitian Xu, Sunny Mai, Licheng Zhang, Abhishek Mishra, Blanca I. Restrepo, Ping-Ying Pan, Shu-Hsia Chen, Chinnaswamy Jagannath
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Tuberculosis is a leading cause of death in mankind due to infectious agents, and Mycobacterium tuberculosis (Mtb) infects and survives in macrophages (MФs). Although MФs are a major niche, myeloid-derived suppressor cells (MDSCs) are an alternativ
Externí odkaz:
https://doaj.org/article/c3f1838cdee54b42bdd451c8e08c2e40
Autor:
Brittany E Jewell, An Xu, Dandan Zhu, Mo-Fan Huang, Linchao Lu, Mo Liu, Erica L Underwood, Jun Hyoung Park, Huihui Fan, Julian A Gingold, Ruoji Zhou, Jian Tu, Zijun Huo, Ying Liu, Weidong Jin, Yi-Hung Chen, Yitian Xu, Shu-Hsia Chen, Nino Rainusso, Nathaniel K Berg, Danielle A Bazer, Christopher Vellano, Philip Jones, Holger K Eltzschig, Zhongming Zhao, Benny Abraham Kaipparettu, Ruiying Zhao, Lisa L Wang, Dung-Fang Lee
Publikováno v:
PLoS Genetics, Vol 17, Iss 12, p e1009971 (2021)
Rothmund-Thomson syndrome (RTS) is an autosomal recessive genetic disorder characterized by poikiloderma, small stature, skeletal anomalies, sparse brows/lashes, cataracts, and predisposition to cancer. Type 2 RTS patients with biallelic RECQL4 patho
Externí odkaz:
https://doaj.org/article/c2342e4657584eb5b330edbc4ecee86b
Autor:
Joseph D Butner, Geoffrey V Martin, Zhihui Wang, Bruna Corradetti, Mauro Ferrari, Nestor Esnaola, Caroline Chung, David S Hong, James W Welsh, Naomi Hasegawa, Elizabeth A Mittendorf, Steven A Curley, Shu-Hsia Chen, Ping-Ying Pan, Steven K Libutti, Shridar Ganesan, Richard L Sidman, Renata Pasqualini, Wadih Arap, Eugene J Koay, Vittorio Cristini
Publikováno v:
eLife, Vol 10 (2021)
Background: Checkpoint inhibitor therapy of cancer has led to markedly improved survival of a subset of patients in multiple solid malignant tumor types, yet the factors driving these clinical responses or lack thereof are not known. We have develope
Externí odkaz:
https://doaj.org/article/fb8dc9b236644627993affff85ba8824
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Externí odkaz:
https://doaj.org/article/d7ea44eb43a0495ab61911780d4cab6f